MicroBiopharm Japan and Main Life entrepreneurs visited Shenzhen Cell Valley
On the afternoon of January 26, Dr. Machida, Ph.D. of the sales planning and development team of MicroBiopharm Japan Pharmaceutical Co., Ltd., and Mr. Wang, business development manager of MainLife Co., Ltd.), visited Shenzhen Cell Valley for an exchange visit.Chairman Shi Yuanyuan Luan Zhishi, Director of the General Office Luan Zhishi , Deputy director of the Quality Management Department Li Rongyou, and Deputy director of the production department Li Huaxiu, warmly received them and held discussions and exchanges on the future development direction of Sino-Japanese biomedicine and the strategic cooperation between the two parties.
First, Director Luan Zhishi of the General Office led the entrepreneurs to visit the exhibition hall, and gave a detailed explanation in Japanese of Shenzhen Cell Valley’s development history, core technologies and recent major breakthroughs in R&D and clinical aspects; then Deputy Director of the Production Department Li Huaxiu and Vice Minister Li Rongyou of the Quality Management Department accompanied him to visit the manufacture workshop and R&D laboratory, and introduced the management mechanism of Shenzhen Cell Valley in ensuring the efficient operation of the production process and the high-quality release of products.
At the symposium, Chairman Shi Yuanyuan extended a warm welcome to the two entrepreneurs and elaborated on Shenzhen Cell Valley’s technological breakthroughs, innovative achievements and clinical success stories in cell and gene therapy. Shenzhen Cell Valley was a one-stop comprehensive outsourcing service providerfocusing on the cell and gene therapy industry in China, and also the only CRO / CDMO company with the industrial production of clinical grade retroviral carrier GMP.Shenzhen Cell Valley has completed its layout in Shenzhen, Beijing, and Zhongshan, and can provide customers with early stage Providing professional and efficient one-stop full industry chain services from research and development, vector design, virus manufacture, cell production to auxiliary declaration. Shenzhen Cell Valley will continue to adhere to the corporate purpose of "Cells benefit all living beings, Genes create the future" and steadily expand overseas Market, give full play to the advantages of retroviral vectors in the industrialization of cell therapy drugs, provide innovative ideas for the advancement of basic research, and provide epoch-making solutions for the treatment of cancer and rare diseases.
Dr. Machida and Mr. Wang highly affirmed the strategic layout of Shenzhen Cell Valley, and gave a detailed explanation of MicroBiopharm Japan's company development history, core business, customer service, production base and core competitiveness. Based on the two parties' full understanding of their respective business sectors, core products, service customers, and relevant overseas regulations in China and Japan, they deeply discussed the points of cooperation and reached a consensus on the future direction of biopharmaceutical development.
This exchange visit laid a solid foundation for future cooperation between the two parties. Both parties look forward to exploring new possibilities in the field of cancer and other disease treatment and medical research, and contributing to the high-quality development of the cell and gene therapy industry.
